{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:07:06Z","timestamp":1790165226159,"version":"4.1.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012112","name":"Swedish Orphan Biovitrum AB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.rpth.2026.106862","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:48:24Z","timestamp":1784098104000},"page":"106862","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Extravascular distribution of factor IX\u2014review of experimental and clinical evidence, and relevance for hemophilia B replacement therapy"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5429-8437","authenticated-orcid":false,"given":"C\u00e9dric","family":"Hermans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0802-5280","authenticated-orcid":false,"given":"Carmen","family":"Escuriola Ettingshausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8268-3268","authenticated-orcid":false,"given":"Michael","family":"Laffan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9902-4074","authenticated-orcid":false,"given":"Davide","family":"Matino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7005-5328","authenticated-orcid":false,"given":"Niamh","family":"O\u2019Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9509-9415","authenticated-orcid":false,"suffix":"Jr.","given":"Robert F.","family":"Sidonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3999-8747","authenticated-orcid":false,"given":"Rolf","family":"Ljung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2026.106862_bib1","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1055\/a-1945-9429","article-title":"Insights into the molecular genetic of hemophilia A and hemophilia B: the relevance of genetic testing in routine clinical practice","volume":"42","author":"Pezeshkpoor","year":"2022","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.rpth.2026.106862_bib2","first-page":"344","article-title":"Diagnosis and treatment of hemophilia","volume":"17","author":"Kizilocak","year":"2019","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.rpth.2026.106862_bib3","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.3324\/haematol.2019.221093","article-title":"Hemophilia A and B: molecular and clinical similarities and differences","volume":"104","author":"Castaman","year":"2019","journal-title":"Haematologica"},{"issue":"suppl 6","key":"10.1016\/j.rpth.2026.106862_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106862_bib5","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7326\/M19-1208","article-title":"Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries","volume":"171","author":"Iorio","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rpth.2026.106862_bib6","doi-asserted-by":"crossref","DOI":"10.1177\/20406207251409300","article-title":"Nine areas with outstanding challenges for hemophilia B research","volume":"17","author":"Astermark","year":"2026","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.rpth.2026.106862_bib7","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.hoc.2021.07.008","article-title":"Hemophilia B (factor IX deficiency)","volume":"35","author":"Sidonio","year":"2021","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.rpth.2026.106862_bib8","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1182\/blood.2023023276","article-title":"Blood coagulation factor IX: structural insights impacting hemophilia B therapy","volume":"144","author":"Bos","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106862_bib9","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1182\/blood.2018884015","article-title":"Dysfunctional endogenous FIX impairs prophylaxis in a mouse hemophilia B model","volume":"133","author":"Cooley","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106862_bib10","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Definitions in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"Blanchette","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106862_bib11","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood.2019000658","article-title":"Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A","volume":"134","author":"van den Berg","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106862_bib12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3324\/haematol.2019.239160","article-title":"Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study","volume":"106","author":"Male","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2026.106862_bib13","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2017-08-801662","article-title":"Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?","volume":"130","author":"Lenting","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106862_bib14","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/jth.13249","article-title":"Collagen-mediated hemostasis","volume":"14","author":"Manon-Jensen","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106862_bib15","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1538-7836.2004.00665.x","article-title":"The role of collagen in thrombosis and hemostasis","volume":"2","author":"Farndale","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106862_bib16","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1161\/ATVBAHA.118.310367","article-title":"Thrombotic regulation from the endothelial cell perspectives","volume":"38","author":"Wang","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"suppl 1","key":"10.1016\/j.rpth.2026.106862_bib17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12959-016-0104-2","article-title":"Extravascular FIX and coagulation","volume":"14","author":"Stafford","year":"2016","journal-title":"Thromb J"},{"key":"10.1016\/j.rpth.2026.106862_bib18","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/blood-2016-05-713040","article-title":"Fill \u2018er up? Fill what up?","volume":"128","author":"Lollar","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106862_bib19","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/MBC.0000000000000969","article-title":"Evaluating the potential benefits of the extravascular pool of factor IX","volume":"32","author":"Lillicrap","year":"2021","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.rpth.2026.106862_bib20","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1160\/TH16-12-0942","article-title":"Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates","volume":"117","author":"Iorio","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106862_bib21","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/0006-291X(83)90365-0","article-title":"Binding of coagulation factors IX and X to the endothelial cell surface","volume":"111","author":"Heimark","year":"1983","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.rpth.2026.106862_bib22","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1073\/pnas.80.13.4119","article-title":"Binding of factors IX and IXa to cultured vascular endothelial cells","volume":"80","author":"Stern","year":"1983","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.rpth.2026.106862_bib23","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1365-2141.1987.tb01303.x","article-title":"In vivo evidence of intravascular binding sites for coagulation factor IX","volume":"66","author":"Stern","year":"1987","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2026.106862_bib24","doi-asserted-by":"crossref","first-page":"11068","DOI":"10.1073\/pnas.93.20.11068","article-title":"Identification of the endothelial cell binding site for factor IX","volume":"93","author":"Cheung","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.rpth.2026.106862_bib25","doi-asserted-by":"crossref","first-page":"16717","DOI":"10.1074\/jbc.272.27.16717","article-title":"Human factor IX binds to specific sites on the collagenous domain of collagen IV","volume":"272","author":"Wolberg","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.rpth.2026.106862_bib26","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ajh.2830500202","article-title":"Coagulant proteins and thrombin generation in synovial fluid: a model for extravascular coagulation","volume":"50","author":"Chang","year":"1995","journal-title":"Am J Hematol"},{"key":"10.1016\/j.rpth.2026.106862_bib27","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1182\/blood.V100.1.153","article-title":"Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo","volume":"100","author":"Gui","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106862_bib28","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1111\/j.1538-7836.2009.03545.x","article-title":"Abnormal hemostasis in a knock-in mouse carrying a variant of factor IX with impaired binding to collagen type IV","volume":"7","author":"Gui","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106862_bib29","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1111\/jth.12421","article-title":"Evidence of clinically significant extravascular stores of factor IX","volume":"11","author":"Feng","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106862_bib30","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/blood-2016-01-696104","article-title":"Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B mice","volume":"128","author":"Cooley","year":"2016","journal-title":"Blood"},{"issue":"suppl 2","key":"10.1016\/j.rpth.2026.106862_bib31","article-title":"Exploring the hemostatic properties of extravascular factor IX in a hemophilia B mouse model [abstract OC 04.1]","volume":"7","author":"Chu","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106862_bib32","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1055\/a-2090-9739","article-title":"Modulation of extravascular binding of recombinant factor IX impacts the duration of efficacy in mouse models","volume":"123","author":"Machado","year":"2023","journal-title":"Thromb Haemost"},{"issue":"suppl 1","key":"10.1016\/j.rpth.2026.106862_bib33","first-page":"1061","article-title":"Extravascular distribution of conventional and EHL FIX products using in vivo spect imaging analysis in hemophilia B mice","volume":"130","author":"Salas","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106862_bib34","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/hae.14300","article-title":"The function of extravascular coagulation factor IX in haemostasis","volume":"27","author":"Mann","year":"2021","journal-title":"Haemophilia"},{"issue":"suppl 2","key":"10.1016\/j.rpth.2026.106862_bib35","article-title":"FIX is localised in the vessel wall and can generate thrombin when in complex with collagen IV in human synovial tissues [abstract OC 36.1]","volume":"8","author":"Morrow","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106862_bib36","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jtha.2023.11.023","article-title":"Extravascular factor IX pool fed by prophylaxis is a true hemostatic barrier against bleeding","volume":"22","author":"Leuci","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106862_bib37","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1046\/j.1365-2516.2003.00762.x","article-title":"The pharmacokinetics of clotting factor therapy","volume":"9","author":"Berntorp","year":"2003","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106862_bib38","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1182\/blood-2011-09-382846","article-title":"Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients","volume":"119","author":"Powell","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106862_bib39","first-page":"27","article-title":"New developments in the management of moderate-to-severe hemophilia B","volume":"7","author":"Nazeef","year":"2016","journal-title":"J Blood Med"},{"key":"10.1016\/j.rpth.2026.106862_bib40","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1055\/s-0038-1653868","article-title":"Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study Group","volume":"73","author":"White","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106862_bib46","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1055\/s-0038-1649902","volume":"74","author":"Prowse","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106862_bib47","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3390\/jcm6030035","article-title":"The history of clotting factor concentrates pharmacokinetics","volume":"6","author":"Morfini","year":"2017","journal-title":"J Clin Med"},{"key":"10.1016\/j.rpth.2026.106862_bib48","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/hae.14727","article-title":"Pharmacokinetic parameters of recombinant factor IX Fc fusion protein are not influenced by factor IX antigen levels in subjects from the phase 3 B-LONG trial","volume":"29","author":"Sidonio","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106862_bib49","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/hae.12188","article-title":"Population pharmacokinetics of recombinant factor IX: implications for dose tailoring","volume":"19","author":"Bj\u00f6rkman","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106862_bib50","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s00228-021-03111-2","article-title":"In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates","volume":"77","author":"Preijers","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.rpth.2026.106862_bib51","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40262-013-0129-7","article-title":"Population pharmacokinetic modelling of recombinant factor IX Fc fusion protein (rFIXFc) in patients with haemophilia B","volume":"53","author":"Diao","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.rpth.2026.106862_bib52","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/rth2.12192","article-title":"Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX-Fc fusion protein: a randomized trial","volume":"3","author":"Escuriola Ettingshausen","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106862_bib53","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1111\/jth.13444","article-title":"Population pharmacokinetics of a new long-acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B","volume":"14","author":"Zhang","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106862_bib54","doi-asserted-by":"crossref","first-page":"8767","DOI":"10.1074\/jbc.273.15.8767","article-title":"Glomerular basement membrane. Identification of a novel disulfide-cross-linked network of alpha3, alpha4, and alpha5 chains of type IV collagen and its implications for the pathogenesis of Alport syndrome","volume":"273","author":"Gunwar","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.rpth.2026.106862_bib55","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1021\/bi00121a031","article-title":"The endothelial cell binding determinant of human factor IX resides in the gamma-carboxyglutamic acid domain","volume":"31","author":"Toomey","year":"1992","journal-title":"Biochemistry"},{"key":"10.1016\/j.rpth.2026.106862_bib56","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1002\/psp4.13159","article-title":"PBPK modeling of recombinant factor IX Fc fusion protein (rFIXFc) and rFIX to characterize the binding to type 4 collagen in the extravascular space","volume":"13","author":"Cloesmeijer","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.rpth.2026.106862_bib57","doi-asserted-by":"crossref","first-page":"9418","DOI":"10.1021\/bi00492a016","article-title":"Proteolytic activation of human factors IX and X by recombinant human factor VIIa: effects of calcium, phospholipids, and tissue factor","volume":"29","author":"Komiyama","year":"1990","journal-title":"Biochemistry"},{"key":"10.1016\/j.rpth.2026.106862_bib58","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1111\/j.1538-7836.2007.02576.x","article-title":"Tissue factor around dermal vessels has bound factor VII in the absence of injury","volume":"5","author":"Hoffman","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106862_bib59","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s42003-025-07838-x","article-title":"Extravascular coagulation regulates haemostasis independently of activated platelet surfaces in an in vivo mouse model","volume":"8","author":"Sakata","year":"2025","journal-title":"Commun Biol"},{"key":"10.1016\/j.rpth.2026.106862_bib60","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1016\/j.jtha.2025.07.036","article-title":"Protease domain exosites regulate extravascular binding of factor IX(a)","volume":"23","author":"Westmark","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106862_bib61","doi-asserted-by":"crossref","first-page":"20529","DOI":"10.1016\/S0021-9258(19)36713-4","article-title":"The binding of human factor IX to endothelial cells is mediated by residues 3-11","volume":"267","author":"Cheung","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/j.rpth.2026.106862_bib62","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1111\/hae.12451","article-title":"Validation of the manufacturing process used to produce long-acting recombinant factor IX Fc fusion protein","volume":"20","author":"McCue","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106862_bib63","first-page":"365","article-title":"Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias","volume":"8","author":"Mancuso","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.rpth.2026.106862_bib64","doi-asserted-by":"crossref","first-page":"6363","DOI":"10.1074\/jbc.M117.817064","article-title":"Half-life-extended recombinant coagulation factor IX-albumin fusion protein is recycled via the FcRn-mediated pathway","volume":"293","author":"Chia","year":"2018","journal-title":"J Biol Chem"},{"key":"10.1016\/j.rpth.2026.106862_bib65","author":"Behring"},{"key":"10.1016\/j.rpth.2026.106862_bib66","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1111\/hae.13896","article-title":"Excessive breakthrough bleeding in haemophilia B patients on factor IX-albumin fusion protein prophylactic therapy: a single centre case series","volume":"26","author":"Kleiboer","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106862_bib67","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ejps.2016.06.025","article-title":"Pharmacokinetics, tissue distribution, excretion, and metabolite profiling of PEGylated rFIX (nonacog beta pegol, N9-GP) in rats","volume":"92","author":"Sternebring","year":"2016","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.rpth.2026.106862_bib68","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1182\/blood-2011-02-336172","article-title":"Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide","volume":"118","author":"\u00d8stergaard","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106862_bib69","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","article-title":"Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research","volume":"15","author":"Signorovitch","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.rpth.2026.106862_bib70","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/0272989X17725740","article-title":"Methods for population-adjusted indirect comparisons in health technology appraisal","volume":"38","author":"Phillippo","year":"2018","journal-title":"Med Decis Making"},{"key":"10.1016\/j.rpth.2026.106862_bib71","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.2147\/IJGM.S464226","article-title":"The importance of clinical context and consistency in methodology when using matching-adjusted indirect comparisons (MAICs) to compare outcomes","volume":"17","author":"Batt","year":"2024","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.rpth.2026.106862_bib72","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2147\/JBM.S389094","article-title":"Efficacy of rFIXFc versus N9-GP prophylaxis in patients with hemophilia B: matching-adjusted indirect comparison of B-LONG and PARADIGM 2 trials","volume":"14","author":"Mancuso","year":"2023","journal-title":"J Blood Med"},{"key":"10.1016\/j.rpth.2026.106862_bib73","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa1305074","article-title":"Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B","volume":"369","author":"Powell","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106862_bib74","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1182\/blood-2014-05-573055","article-title":"Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial","volume":"124","author":"Collins","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106862_bib75","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2147\/JBM.S312885","article-title":"Efficacy of rFIXFc versus rIX-FP for the treatment of patients with hemophilia B: matching-adjusted indirect comparison of B-LONG and PROLONG-9FP trials","volume":"12","author":"Astermark","year":"2021","journal-title":"J Blood Med"},{"key":"10.1016\/j.rpth.2026.106862_bib76","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1182\/blood-2015-09-669234","article-title":"Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial","volume":"127","author":"Santagostino","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106862_bib77","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s12325-023-02745-1","article-title":"Matching-adjusted indirect comparison of recombinant factor IX albumin fusion protein versus recombinant factor IX Fc fusion protein for weekly prophylactic treatment of hemophilia B","volume":"41","author":"Guillet","year":"2024","journal-title":"Adv Ther"},{"issue":"suppl 1","key":"10.1016\/j.rpth.2026.106862_bib78","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1182\/blood-2019-126196","article-title":"Spontaneous bleeding and poor bleeding response with extended half-life factor IX products: a survey of select US and Canadian hemophilia treatment centers","volume":"134","author":"Malec","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106862_bib79","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.1111\/hae.13943","article-title":"Spontaneous bleeding and poor bleeding response with extended half-life factor IX products: a survey of select US haemophilia treatment centres","volume":"26","author":"Malec","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106862_bib80","doi-asserted-by":"crossref","first-page":"4583","DOI":"10.1007\/s12325-025-03303-7","article-title":"Real-world prophylaxis outcomes with rIX-FP and rFIXFc for males with hemophilia B: pooled analysis of medical chart data from Germany and Italy","volume":"42","author":"Oldenburg","year":"2025","journal-title":"Adv Ther"},{"key":"10.1016\/j.rpth.2026.106862_bib81","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1007\/s12325-025-03336-y","article-title":"Comparing real-world outcomes of prophylaxis with extended half-life factor IX (rIX-FP vs. rFIXFc and N9-GP) for haemophilia B: an analysis of medical chart data from Germany","volume":"42","author":"Olivieri","year":"2025","journal-title":"Adv Ther"},{"key":"10.1016\/j.rpth.2026.106862_bib82","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/hae.12878","article-title":"Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B","volume":"22","author":"Kavakli","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106862_bib83","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/MBC.0000000000001012","article-title":"Once-weekly prophylaxis regimen of nonacog alfa in patients with hemophilia B: an analysis of timing of bleeding event onset","volume":"32","author":"Tortella","year":"2021","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"suppl 2","key":"10.1016\/j.rpth.2026.106862_bib84","article-title":"Association between FIX levels & bleeding rates in hemophilia B patients receiving rFIXFc or N9-GP","volume":"9","author":"Iorio","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106862_bib85","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/cpt.3724","article-title":"Erratum to \u201cRelationship between dose, factor IX activity levels and bleeding probability for rIX-FP prophylaxis in hemophilia B: a repeated time-to-event analysis\u201d","volume":"118","author":"Koopman","year":"2025","journal-title":"Clin Pharmacol Ther"},{"issue":"suppl 1","key":"10.1016\/j.rpth.2026.106862_bib86","first-page":"36","article-title":"Detection of factor IX molecules in liver and paws of hemophilia-B mice [abstract PO026]","volume":"29","author":"Enjolras","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106862_bib87","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/MBC.0000000000001230","article-title":"Biodistribution of recombinant factor IX, extended half-life recombinant factor IX Fc fusion protein, and glycoPEGylated recombinant factor IX in hemophilia B mice","volume":"34","author":"van der Flier","year":"2023","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.rpth.2026.106862_bib88","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/hae.14324","article-title":"Plasma factor IX: the tip of the iceberg?","volume":"27","author":"Sidonio","year":"2021","journal-title":"Haemophilia"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S247503792603520X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S247503792603520X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:52:41Z","timestamp":1790164361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S247503792603520X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":83,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S247503792603520X"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106862","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extravascular distribution of factor IX\u2014review of experimental and clinical evidence, and relevance for hemophilia B replacement therapy","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106862","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"106862"}}